Anticoagulants are medicines that prevent the clotting of blood. They are also known as blood thinners. However, they do not actually thin the blood. Anticoagulants are substances that work against (anti-) the process of blood clotting. The very first anticoagulant to be discovered was heparin. It was introduced in the 1930s. The improvement and development of anticoagulant drugs has continued since then. Heparin and warfarin were traditional anticoagulants. Their role in the prevention and treatment of thromboembolic diseases was established through evidence from clinical trials. Now, anticoagulant drugs are widely used in medicine. However, anticoagulant drugs entail many disadvantages. For instance, the complete effects of pharmacokinetics and pharmacodynamics are still not known. They may lead to an increased risk of bleeding after drug intake. Laboratory examination of these drugs before prescription is necessary to adjust doses for patients.
Anticoagulants are medicines that help in the treatment and prevention of blood clots that occur in blood vessels. Veins or arteries can get blocked because of blood clots. A blood clot in a large vein may cause deep vein thrombosis (DVT) and many more health-related problems. A blocked artery can stop the supply of oxygen and flow of blood to various parts of the body. There is a need for continuous supply of oxygen and blood to vital parts of the body such as the heart, brain, and lungs. Tissues receiving blood and oxygen from blocked arteries have detrimental effects or may cause death. This might lead to serious health issues such as a heart attack or stroke. Blocking of vitamin K helps prevent blood clots from forming without much effort. The blocking increases the time needed to make fibrin. Normal medicines usually take two or three days to work fully. For instant and immediate response, anticoagulants are used. Dabigatran, edoxaban, rivaroxaban, and apixaban prevent a particular type of chemical present in the blood, known as thrombin, from getting activated. This stops fibrinogen from producing fibrin in the blood. Dabigatran is bonded to thrombin. Rivaroxaban and apixaban stop the reaction and avoid thrombin from being formed. All four medicines work immediately and quickly within a span of two to four hours. Anticoagulants are mostly used for common conditions such as deep vein thrombosis (DVT) and clots in the lungs known as pulmonary embolus (PE). In such cases, anticoagulants prevent the clot from getting bigger. Another reason for the usage of anticoagulants is the prevention of risk of forming a blood clot.
A major factor expected to drive the global oral anticoagulants market is rise in the adoption of drugs, particularly among geriatric patients, who are at a higher risk of heart attacks and strokes. Moreover, factors such as rapid onset of action, short half-life, and little or no food interaction are likely to boost the market. However, factors such as prohibitively high cost resulting in poor compliance, lack of a single specific antidote, and serious bleeding in renal impaired patients are anticipated to hamper the market during the forecast period.
The global oral anticoagulant market has been segmented based on disease indication, distribution channel, and region. Based on disease indication, the global oral anticoagulant market can be segmented into proximal deep vein thrombosis (DVT), arterial and venous thrombosis, paroxysmal nocturnal haemoglobinuria, and others. In terms of distribution channel, the global oral anticoagulant market can be segmented into hospital pharmacies, retail pharmacies, and drug stores.
In terms of region, the global oral anticoagulant market can be segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, and Middle East & Africa. North America is expected to dominate the global oral anticoagulant market due to the presence of a higher number of laboratory developed tests and advanced technologies. Europe is expected to be a prominent region of the global oral anticoagulant market.
Prominent players operating in the global oral anticoagulant market are Boehringer Ingelheim International GmbH., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Sanofi, Cosmo Pharmaceuticals, Pfizer Inc., AstraZeneca, Bayer AG, Innovation, CSL, Eisai Co., Ltd., GlaxoSmithKline plc., and Bausch Health among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.